New drug boosts chemo to fight breast cancer before surgery
NCT ID NCT07102940
Summary
This study is testing whether adding an immunotherapy drug called eftilagimod alpha (Efti) to standard chemotherapy given before surgery can help eliminate more cancer in patients with early-stage, hormone-positive, HER2-negative breast cancer. The main goal is to see if this combination leads to a 'pathological complete response,' meaning no detectable cancer is found in the breast tissue removed during surgery. About 50 participants will receive the drug combination, and researchers will monitor how the tumor responds both during treatment and after surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.